128 related articles for article (PubMed ID: 23026838)
1. The effect of race-ethnicity and geography on adoption of innovations in the treatment of schizophrenia.
Horvitz-Lennon M; Alegría M; Normand SL
Psychiatr Serv; 2012 Dec; 63(12):1171-7. PubMed ID: 23026838
[TBL] [Abstract][Full Text] [Related]
2. The effect of race-ethnicity on the comparative effectiveness of clozapine among Medicaid beneficiaries.
Horvitz-Lennon M; Donohue JM; Lave JR; Alegría M; Normand SL
Psychiatr Serv; 2013 Mar; 64(3):230-7. PubMed ID: 23242347
[TBL] [Abstract][Full Text] [Related]
3. Disparities in quality of care among publicly insured adults with schizophrenia in four large U.S. states, 2002-2008.
Horvitz-Lennon M; Volya R; Donohue JM; Lave JR; Stein BD; Normand SL
Health Serv Res; 2014 Aug; 49(4):1121-44. PubMed ID: 24628414
[TBL] [Abstract][Full Text] [Related]
4. Where You Live Matters: Quality and Racial/Ethnic Disparities in Schizophrenia Care in Four State Medicaid Programs.
Horvitz-Lennon M; Volya R; Garfield R; Donohue JM; Lave JR; Normand SL
Health Serv Res; 2015 Oct; 50(5):1710-29. PubMed ID: 25759240
[TBL] [Abstract][Full Text] [Related]
5. Racial and ethnic disparities in the treatment of a Medicaid population with schizophrenia.
Horvitz-Lennon M; McGuire TG; Alegria M; Frank RG
Health Serv Res; 2009 Dec; 44(6):2106-22. PubMed ID: 19780855
[TBL] [Abstract][Full Text] [Related]
6. "Impact of drug-reimbursement policies on prescribing: A case-study of a newly marketed long-acting injectable antipsychotic among relapsed schizophrenia patients".
Jackson JW; Fulchino L; Rogers J; Mogun H; Polinski J; Henderson DC; Schneeweiss S; Fischer MA
Pharmacoepidemiol Drug Saf; 2018 Jan; 27(1):95-104. PubMed ID: 29168261
[TBL] [Abstract][Full Text] [Related]
7. Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics.
Pilon D; Tandon N; Lafeuille MH; Kamstra R; Emond B; Lefebvre P; Joshi K
Clin Ther; 2017 Oct; 39(10):1972-1985.e2. PubMed ID: 28919292
[TBL] [Abstract][Full Text] [Related]
8. Duration of pharmacotherapy with long-acting injectable risperidone in the treatment of schizophrenia.
Mohamed S; Rosenheck R; Harpaz-Rotem I; Leslie D; Sernyak MJ
Psychiatr Q; 2009 Dec; 80(4):241-9. PubMed ID: 19768543
[TBL] [Abstract][Full Text] [Related]
9. Switching from risperidone long-acting injectable to paliperidone long-acting injectable or oral antipsychotics: analysis of a Medicaid claims database.
Voss EA; Ryan PB; Stang PE; Hough D; Alphs L
Int Clin Psychopharmacol; 2015 May; 30(3):151-7. PubMed ID: 25730525
[TBL] [Abstract][Full Text] [Related]
10. Racial differences in antipsychotic use: Claims database analysis of Medicaid-insured patients with schizophrenia.
Lawson W; Johnston S; Karson C; Offord S; Docherty J; Eramo A; Kamat S; Blanchette CM; Carson W; Nasrallah HA
Ann Clin Psychiatry; 2015 Nov; 27(4):242-52. PubMed ID: 26554365
[TBL] [Abstract][Full Text] [Related]
11. Treatment discontinuation of long-acting injectables or oral atypical antipsychotics among Medicaid recipients with schizophrenia.
Song X; El Khoury AC; Brouillette M; Smith D; Joshi K
J Med Econ; 2019 Nov; 22(11):1105-1112. PubMed ID: 31062998
[No Abstract] [Full Text] [Related]
12. Racial-ethnic differences in incident olanzapine use after an FDA advisory for patients with schizophrenia.
Dusetzina SB; Cook BL; Busch AB; Alexander GC; Huskamp HA
Psychiatr Serv; 2013 Jan; 64(1):83-7. PubMed ID: 23280461
[TBL] [Abstract][Full Text] [Related]
13. Association between second-generation antipsychotic medication half-life and hospitalization in the community treatment of adult schizophrenia.
Broder MS; Bates JA; Jing Y; Hebden T; Forbes RA; Chang E
J Med Econ; 2012; 15(1):105-11. PubMed ID: 21991926
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness, Adverse Effects and Drug Compliance of Long-Acting Injectable Risperidone in Children and Adolescents.
Ceylan MF; Erdogan B; Tural Hesapcioglu S; Cop E
Clin Drug Investig; 2017 Oct; 37(10):947-956. PubMed ID: 28726075
[TBL] [Abstract][Full Text] [Related]
15. The effectiveness of long-acting injectable risperidone in a population of psychiatric out-patients: 1-year naturalistic study.
Di Lorenzo R; Fiorini F; Santachiara S
Psychopharmacol Bull; 2010; 43(1):39-52. PubMed ID: 20581799
[TBL] [Abstract][Full Text] [Related]
16. Statistical Approaches for Quantifying the Quality of Neurosurgical Care.
Normand ST; Zelevinsky K; Abing HK; Horvitz-Lennon M
World Neurosurg; 2022 May; 161():331-342.e1. PubMed ID: 35505552
[TBL] [Abstract][Full Text] [Related]
17. Olanzapine versus risperidone in the treatment of schizophrenia : a comparison of costs among Texas Medicaid recipients.
Rascati KL; Johnsrud MT; Crismon ML; Lage MJ; Barber BL
Pharmacoeconomics; 2003; 21(10):683-97. PubMed ID: 12828491
[TBL] [Abstract][Full Text] [Related]
18. Adherence, persistence, and inpatient utilization among adult schizophrenia patients using once-monthly versus twice-monthly long-acting atypical antipsychotics.
Pilon D; Alcusky M; Xiao Y; Thompson-Leduc P; Lafeuille MH; Lefebvre P; Benson C
J Med Econ; 2018 Feb; 21(2):135-143. PubMed ID: 28895766
[TBL] [Abstract][Full Text] [Related]
19. Antipsychotic exposure and type 2 diabetes among patients with schizophrenia: a matched case-control study of California Medicaid claims.
Lambert BL; Chou CH; Chang KY; Tafesse E; Carson W
Pharmacoepidemiol Drug Saf; 2005 Jun; 14(6):417-25. PubMed ID: 15786516
[TBL] [Abstract][Full Text] [Related]
20. Prevalence, utilization patterns, and predictors of antipsychotic polypharmacy: experience in a multistate Medicaid population, 1998-2003.
Morrato EH; Dodd S; Oderda G; Haxby DG; Allen R; Valuck RJ
Clin Ther; 2007 Jan; 29(1):183-95. PubMed ID: 17379060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
